Mauna Kea Technologies Announces Results of its 2023 Ordinary and Extraordinary Annual General Meeting
Shareholders approved all proposed resolutions
Paris and Boston, June 5, 2023 - 5:45 pm CEST - Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary miniprobe and needle confocal laser endomicroscopy (p/nCLE) platform, held its ordinary and extraordinary annual general meeting of shareholders on June 2, 2023, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of directors and CEO.
With a quorum of 31.7%, the shareholders have adopted all the resolutions recommended by the Board of Directors, including the annual and consolidated financial statements for the 2022 financial year, the compensation policy applicable to the Chief Executive Officer and to the Directors, as well as delegations granted to the Board of Directors related to financial transactions.
In accordance with the provisions of Article L. 421-14 of the French Monetary and Financial Code, the Shareholders also approved the proposed transfer of the Company's shares from the regulated market of Euronext Paris (Compartment C) to Euronext Growth Paris and granted full powers to the Board of Directors to implement the transfer of listing, if applicable.
Details on the vote results are available on the company’s website.